thebiostories

Phase 1 Clinical Trials of MK-7602: A Promising New Chapter in the Fight Against Malaria From Laboratory Discovery to Human Trials Every new antimalarial medicine begins with a simple question: Can scientists stay ahead of one of humanity's oldest and most adaptable killers? For decades, malaria parasites have repeatedly evolved resistance to medicines that once transformed global malaria control. Each time a highly effective treatment has been introduced, the parasite has eventually found new ways to survive, creating an urgent need for drugs with entirely different mechanisms of action. In March 2026, researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) reached an important milestone in that ongoing battle. Early clinical trial results showed that the experimental antimalarial drug MK-7602 was well tolerated in healthy volunteers and achieved blood concentrations predicted to effectively kill malaria parasites. Although Phase 1 clinical trials are d...

How WEHI Scientists Are Helping Defeat Malaria: From Fundamental Discovery to New Treatments Why Malaria Still Matters Malaria has been one of humanity's deadliest infectious diseases for thousands of years. Although remarkable progress has been made over the past two decades, the disease still causes hundreds of thousands of deaths every year, with young children in sub-Saharan Africa carrying the greatest burden. Drug-resistant parasites, insecticide-resistant mosquitoes, and the parasite's remarkably complex life cycle continue to challenge scientists around the world. These challenges mean that new medicines cannot rely on improving existing drugs alone. Scientists must also uncover entirely new biological vulnerabilities within the parasite itself. For decades, researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne have contributed to this global effort by asking one fundamental question: How does the malaria parasite survive ins...